| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms alphaCD30-vcMMAE, alphaCD70-mcMMAF, antibody-drug conjugates(Seattle Genetics/Oxford BioTherapeutics) | 
| Target | 
| Action inhibitors | 
| Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), Tubulin inhibitors | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | - | |
| Neoplasms | Preclinical | United Kingdom  | - | 






